Investing.com - Jasper Therapeutics (NASDAQ: JSPR) reported third quarter EPS of $-0.160, worse than the analyst estimate of $-0.155. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Jasper Therapeutics's stock price closed at $0.740. It is down -46.760% in the last 3 months and up 10.000% in the last 12 months.
Jasper Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Jasper Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Jasper Therapeutics's Financial Health score is "fair performance".
Check out Jasper Therapeutics's recent earnings performance, and Jasper Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar